Equillium Inc (EQ)
1.43
+0.03
(+2.14%)
USD |
NASDAQ |
May 24, 13:29
Equillium Cash from Investing (TTM): 17.59M for March 31, 2024
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 17.59M |
December 31, 2023 | -4.762M |
September 30, 2023 | 7.782M |
June 30, 2023 | 11.80M |
March 31, 2023 | 5.488M |
December 31, 2022 | 18.68M |
September 30, 2022 | -5.183M |
June 30, 2022 | -9.715M |
March 31, 2022 | 10.56M |
December 31, 2021 | 27.41M |
September 30, 2021 | 27.26M |
Date | Value |
---|---|
June 30, 2021 | -6.225M |
March 31, 2021 | -26.74M |
December 31, 2020 | -18.59M |
September 30, 2020 | -6.886M |
June 30, 2020 | 15.90M |
March 31, 2020 | 13.49M |
December 31, 2019 | -2.166M |
September 30, 2019 | -34.24M |
June 30, 2019 | -34.02M |
March 31, 2019 | -40.08M |
December 31, 2018 | -37.43M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-34.24M
Minimum
Sep 2019
27.41M
Maximum
Dec 2021
0.3713M
Average
1.661M
Median
Cash from Investing (TTM) Benchmarks
Janux Therapeutics Inc | -146.19M |
Mersana Therapeutics Inc | 45.94M |
Vera Therapeutics Inc | -270.95M |
NovaBay Pharmaceuticals Inc | 1.062M |
Palatin Technologies Inc | 9.41M |